Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making

BACKGROUND: It is widely acknowledged that there is value in examining cancers for genomic aberrations via next-generation sequencing (NGS). How commercially available NGS platforms compare with each other, and the clinical utility of the reported actionable results, are not well known. During the c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Onco Targets Ther
Hauptverfasser: Weiss, Glen J, Hoff, Brandi R, Whitehead, Robert P, Sangal, Ashish, Gingrich, Susan A, Penny, Robert J, Mallery, David W, Morris, Scott M, Thompson, Eric J, Loesch, David M, Khemka, Vivek
Format: Artigo
Sprache:Inglês
Veröffentlicht: Dove Medical Press 2015
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4423502/
https://ncbi.nlm.nih.gov/pubmed/25960669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S81995
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge